KC
ITCI

Kintayl Capital’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Kintayl Capital’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,516
Closed -$1.52M – 54
2025
Q1 		$1.52M Buy
+11,516
New +$1.44M 1.07% 28

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Kintayl Capital's ITCI Position: Q2 2025 in Review

Kintayl Capital sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 11,516 shares — an estimated $1.52M sold.

Kintayl Capital first reported a position in ITCI in Q1 2025 and held it in 1 quarter. The position peaked at $1.52M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Kintayl Capital reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Kintayl Capital sold 11,516 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $1.52M.
  • Kintayl Capital first reported a position in Intra-Cellular Therapies Inc. in Q1 2025 and held it in 1 quarter.
  • Kintayl Capital's Intra-Cellular Therapies Inc. position peaked at $1.52M in Q1 2025.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Kintayl Capital's 13F filing for Q2 2025, filed 14 Aug 2025.